Delamanid: First global approval

Drugs

Volumn 74, Issue 9, 2014, Pages 1041-1045

  Ryan, Nicola J ^b   Lo, Jin Han ^a  

^a Adis Level 1 ^*  (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DELAMANID; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; DRUG MARKETING; DRUG PENETRATION; DRUG STRUCTURE; EUROPEAN UNION; HUMAN; JAPAN; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; QT PROLONGATION; RECOMMENDED DRUG DOSE; TUBERCULOSIS; CHEMISTRY; DRUG APPROVAL; DRUG EFFECTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG APPROVAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84904039980     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0241-5     Document Type: Article

References (18)

1. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849-62.
2. Ginsberg AM. Drugs in development for tuberculosis. Drugs. 2010;70:2201-14.
3. Field SK, Fisher D, Jarand JM, Cowie RL. New treatment options for multidrug-resistant tuberculosis. Ther Adv Respir Dis. 2012;6(5):255-68.
4. Villemagne B, Crauste C, Flipo M, Baulard AR, Deprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem. 2012;51:1-16.
5. Otsuka Pharmaceutical. Otsuka Wins European Marketing Authorization for Deltyba(TM) (delamanid). Media Release. 20 Apr 2014. Available at http://www.otsuka.co.jp/en/company/release/2014/0430-01.html. Accessed 14 May 2014.
6. Otsuka Pharmaceutical Co L. Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan - Half Century Since Last Drug Was Approved in Japan for Tuberculosis. Media Release. 27 Mar 2013. Available at http://www.otsuka.co.jp/en/company/ release/2013/0327-01.html. Accessed 14 May 2014.
7. European Medicines Agency. Public summary of opinion on orphan designation. Media Release. 15 Nov 2011. Available at http://www.ema.europa.eu/ docs/en-GB/document-library/Orphan-designation/2009/10/WC500006083.pdf. Accessed 14 May 2014.
8. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151-60.
9. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393-400.
10. Otsuka Pharmaceutical. Summary of Product Characteristics. Available at http://eceuropaeu/health/documents/community-register/2014/20140428126881/ anx-126881-enpdf. Accessed 14 May 2014.
11. European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013. Media Release. 22 Nov 2013. Available at http://www.emea.europa.eu.
12. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(7):949-54.
13. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466.
14. Saliu OY, Crismale C, Schwander SK, Wallis RS. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob Chemother. 2007;60(5):994-8.
15. Zhang Q, Liu Y, Tang S, Sha W, Xiao H. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys. 2013;67(3):957-63.
16. Otsuka Pharmaceutical. Safety and efficacy of delamanid for 6 months in patients with multidrug resistant tuberculosis [NCT01424670]. Available at http://clinicaltrials.gov/ct2/show/NCT01424670?term=delamanid&rank=3. Accessed 14 May 2014.
17. Otsuka Pharmaceutical. Pharmacokinetic and safety trial to determine the appropriate dose for pediatric patients with multidrug resistant tuberculosis [NCT01856634]. Available at http://clinicaltrials.gov/ct2/show/NCT01856634?term= NCT01856634&rank=1. Accessed 14 May 2014.
18. Otsuka Pharmaceutical. A 6-month safety, efficacy and pharmacokinetic trial of delamanid in pediatric patients with multidrug resistant tuberculosis [NCT01859923]. Available at http://clinicaltrials.gov/ct2/show/NCT01859923?term= NCT01859923&rank=1. Accessed 14 May 2014.